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Background: Gastrointestinal (GI) disorders are commonly associated with chronic conditions such as diabetes,
obesity, and hypertension. Direct consequences are obstipation or diarrhea as opposite aspects of the irritable
bowel syndrome, and more indirectly, alteration of appetite, feeling of fullness, flatulence, bloatedness, and
eventually leading to altered absorption of nutrients. Moreover, GI retention and passage times have been
recognized as important factors in determining the release site and hence the bioavailability of orally administered
drugs. To facilitate the understanding of physiological and pathological processes involved, it is necessary to
monitor the gut motility in animal models. Here, we describe a method for studying the GI transit time using
technetium-labeled activated charcoal diethylenetriaminepentaacetic acid (99mTc-Ch-DTPA) detected by single-
photon emission computed tomography (SPECT).
Methods: Tc-DTPA was adsorbed onto activated charcoal and administered orally to trypan blue-tainted (n = 4)
129SvEv mice (50 to 80 MBq/animal, n = 11). The exact distribution and movement of radioactivity in the
gastrointestinal tract was measured at intervals of 1, 3, 6, 12, and 22 h by SPECT-CT. In addition, in order to validate
the imaging of GI transient time, loperamide (0.25 mg/animal, n = 3) was used to delay the GI transit.
Results: The transit time measured as the peak radioactivity occurring in the rectum was 6 to 7 h after gavaging of
99mTc-Ch-DTPA. After 1 h, the bolus had passed into the small intestine and entered the cecum and the colon. At 6
and 8 h, the cecum, the ascending, transverse, and descending colon, and the rectum showed significant labeling.
Several pellets were stored in the rectum for defecation. After 22 h, little activity remained in the stomach and
none was detected in the transverse colon or other GI locations. In contrast, 6 h after administration of loperamide,
only the cecum and part of the transverse colon were labeled. After 22 h, both structures retained significant
amount of label. This delay has been verified by non-radiolabeled dye trypan blue GI measurements (n = 4).
Conclusion: Here, we present the first non-invasive study of mouse GI transit time, allowing clear differentiation
between vehicle- and loperamide-treated animals. This technique is useful for the investigation of GI motility in
mice.
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Measurement of gastrointestinal (GI) transit time is a
very useful clinical and research technique for evaluating
the motility disorders in the gastrointestinal tract. A
number of testing methods are available and used fre-
quently by the clinicians to evaluate the symptoms and
causes of the GI transit, motility, and drug release in
humans. These measurements will provide an assessment
of the overall motility. The abnormality in gastrointestinal
transit is considered as an unfathomable symptom. Nor-
mally, symptoms appearing in one part of the gut may
overlap with symptoms from another; so, using direct
in vivo measurements in transit studies is an important
tool for diagnostic evaluations [1].
A variety of methods have been used for assessing GI
transit times, motility, and drug release. Most well known
is the use of X-ray [2] and scintigraphic techniques [3]
which have been used to observe orally ingested capsules
containing radiopaque substances or gamma emitters, re-
spectively. On the other hand, non-invasive techniques
such as ultrasound [4], metal detectors [5], magnetic field
detectors [6], and dyes [7] have been used to avoid the ad-
verse effects of ionizing radiation. However, all these
methods have limitations due to fundamental constraints
such as low temporal or spatial resolution, lack of balan-
cing anatomical information, or incomplete spatial infor-
mation. Furthermore, such capsules being foreign in
nature and having considerably large size may not reflect
an accurate physiology of the GI tract.
Despite the considerable efforts undertaken by re-
searchers in academia and industry alike during the past
two decades, the success rate for effective drug devel-
opment for irritable bowel syndrome (IBS) and other
functional gastrointestinal disorders did not score sat-
isfactorily [8]. GI motility and functional disorders are
interrelated and are usually expressed as undefined
symptoms, either alone or overlap with each other.
These are presented as two distinct categories; the first
encompasses swallowing disorder, diarrhea, vomiting,
and abnormal pain such as functional dyspepsia and
IBS. The second category refers to esophageal, gastric,
intestinal, and colonic motility and chronic idiopathic
intestinal pseudo-obstruction.
Current in vivo methods are mainly based on single
time point measurements for the small intestine, using
either charcoal or similar inert non-reabsorbable dyes.
Thus far, imaging of radiotracers has been used in
humans but not in small rodents. The large intestine is
especially difficult to assess in mice. The only useful
method is the total GI tract transit time measured using
a tracer passage. The present study establishes a proto-
col for the measurement of gastrointestinal motility in
small animals. The technique described in this study, to
our knowledge, is the first method to measurelongitudinal gastrointestinal motility in mice and would
be useful for the study of pharmacological compounds,
gastrointestinal hormones, and for transgenic animal
models with altered GI motility.
Methods
In this study, we used two contrasting materials for the
labeling study in order to select the best reagent. A com-
parative study was carried out to examine the best prep-
aration for the study; technetium-labeled activated
charcoal diethylenetriaminepentaacetic acid (99mTc-Ch-
DTPA) was either used with activated charcoal or mixed
with resin directly.
Preparation of 99mTc-Amberlite resin for gastrointestinal
transit
Indigestible Amberlite resin pellets (approximately 1 mm
diameter; Sigma-Aldrich, St. Louis, MO, USA) were
radiolabeled with the radioisotope technetium 99mTc, fol-
lowing the method of Theodorakis [9]. Briefly, 2.0 g resin
was stirred in a vial with a solution of 99mTc-sodium
pertechnetate (400 to 500 MBq) in 2 ml saline. The mix-
ture was stirred for 10 min, and the labeled resin was re-
covered by filtration (0.22 μm, Millipore, Billerica, MA,
USA), washed, and then resuspended in distilled water.
The fluid formulation used was a non-absorbable aqueous
solution of 99mTc-labeled Amberlite resin in saline.
Preparation of charcoal-99mTc-DTPA for gastrointestinal
transit
To obtain 99mTc-diethylene-triamine-pentaacetic acid
(99mTc-DTPA), a reducing agent is required, usually tin
ion as Sn(OH)2. It is important to do all the mixing in an
anaerobic atmosphere, e.g., nitrogen. In the preformulated
kits, each vial contains 35 mg of DTPA and 2 mg of stan-
nous chloride dihydrate (SnCl·2H2O) in freeze-dried form
in a nitrogen atmosphere and the pH is adjusted to 4. It
can bind 0.1 to 6 GBq of 99mTc. Five-milligram DTPA was
dissolved in ultrapure water (2 to 4 ml, the amount de-
pends on how many animals are to be gavaged) under
nitrogen atmosphere. Dissolution is facilitated by alka-
linization (add 200 to 300 μL of 1 N NaOH). After dis-
solving DTPA, 0.3 mg Sn(OH)2 is added (1 to 2
crystals). After the solution is adjusted to pH 7, 500 to
1,000 MBq pertechnetate is added followed by incubation
for 5 min in normal atmosphere. Activated charcoal
(50 mg) was mixed with the 99mTc-DTPA. After 2-min
mixing, the charcoal suspension was ready for administration.
SPECT imaging
Single-photon emission computed tomography (SPECT)
imaging was performed with four-headed multiplexing
multipinhole NanoSPECT (Bioscan Inc., Washington D.C.,
USA). Each head was fitted with an application-specific
99mTc-Ch-DTPA 3 hours 99mTc-Amberlite-DTPA 3 hours
Figure 2 Comparison between 99mTc-Ch-DTPA and 99mTc-Amberlite
resin movements in the GI tract after 3 h of gavaging.
A B C D
Figure 1 Movements of 99mTc-Ch-DTPA in the GI tract after 7 h of gavaging. (A) Scheme of mouse GI tract. (B) MIP image of SPECT
after 7 h. (C) Sagittal image of SPECT after 7 h. (D) Coronal image of SPECT after 7 h.
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used a mice aperture (aperture 3), which comprises a total
of 36 individual 1-mm diameter pinholes (nine pinholes in
every collimator, 4 × 9 = 36) providing a maximum reso-
lution of 0.75 mm for SPECT imaging. The NanoSPECT
was calibrated with a phantom, approximately the size of
the animals, filled with known amount of 99mTc. The axial
FOV is extended using a step-and-shoot helical scan of the
animal, with the user defining a range from 24 to 270 mm
according to the region to be imaged. The energy peak for
the camera was set at 140 keV. The mice were scanned at
various time points with an initial activity of approximately
50 to 80 MBq 99mTc-Ch-DTPA. An acquisition time of
30 s per view was chosen, resulting in acquisition times ran-
ging from 30 to 40 min per animal. The 9-min CT imaging
was performed immediately following the whole-body
SPECT imaging with 50-μm resolution. Reconstruction of
the images was performed without including attenuation
correction. Reconstructed data from SPECT and CT were
co-registered using InVivoScope (Bioscan Inc.) for further
analysis and interpretation.
Performance of transit studies in mice
All animal experiments were performed under an In-
stitutional Animal Care and Use Committee (IACUC)-
approved protocol from Takeda Cambridge, Singapore,
and an IACUC-approved imaging service protocol of
Singapore Bioimaging Consortium. Eleven healthy mice
ranging in age between 8 to 12 weeks were used in this
study. The charcoal was gavaged as 0.3 mL of 99mTc-
Ch-DTPA suspension using oral feeding syringe at
time 0. After gavaging of the 99mTc-Ch-DTPA, the ani-
mals were imaged in the NanoSPECT-CT under light
inhalation anesthesia using isoflurane (1% isoflurane in
100% oxygen at a flow rate of 1 L/min). Due to shortduration of the anesthesia and short recovery time, a
major effect of anesthesia on GI motility is not
expected. To visualize the path traveled by the char-
coal along the total length of the gastrointestinal tract,
temporal images were collected for post-acquisition
analysis. SPECT scans were obtained at 0, 1, 3, 6, and
22 h after ingestion of the 99mTc-Ch-DTPA. The GIT
(gastrointestinal transit) was determined by identifying the
leading front of intragastrically administered charcoal-
labeled radiotracer in the GI tract. The GIT was calculated
using the 99mTc-Ch-DTPA movements on the basis of the
activity residing in various locations within the GI tract.
The total radiotracer activity at a given time point was
99mTc-Ch-DTPA 1 hour 99mTc-Ch-DTPA 3 hours
Figure 3 99mTc-Ch-DTPA movements in the GI tract after 1 and
3 h of gavaging.
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HiSPECT software (Bioscan Inc.).
Drug treatment
Two sets of male 129SvEv animals (3 to 5 months old,
body weight 25 to 30 g) were used for the drug study:
control- and loperamide-treated groups. The charcoal
was mixed with the 99mTc-DTPA and gavaged 30 min
after loperamide administration (0.25 mg per animal via
gavage) [10] in the drug study group and vehicle in con-
trol group. The loperamide dose was selected based on
published data. The SPECT scans were obtained at 0, 1,
3, 6, and 22 h after ingestion of the 99mTc-Ch-DTPA.
Once the drug was given to the animals, they were
allowed to reside in separate cages with ad libitum access
to food and water. The animals were imaged at specified
time points, and data were used for post-acquisition
analysis.
GIT measurement using trypan blue dye
Four healthy mice ranging in age between 8 and 12
weeks were used in this study; the charcoal (2.0 g) was
mixed with 0.4% trypan blue and gavaged (0.3 ml) with





Transit measurements in the G
1 1 h and 10 min Stomach and small intestine are
2 3 h Stomach and small intestines are
3 6 h Whole GI tract is prominently lab
prominent labeling of the colon
4 8 h The transverse colon, descending
5 22 h Only little activity remains in thesacrificed at varying time points viz. 1, 3, 6, and 22. At
the first time point, the abdomen was opened and the
stomach was examined at the cardiac and pyloric ends.
This correlates with the concentration of trypan blue in
the stomach. The other time points were the same as
those used for the 99mTc-Ch-DTPA measurements. The
small intestine, cecum, transverse colon and large intes-
tine loop, and colon region of trypan blue traveling time
were recorded and compared with the SPECT images
of 99mTc-Ch-DTPA. The total travel time of GIT was
determined on the basis of the excretion of first fecal pel-
let tainted with trypan blue. The color of the pellets was
compared with those from the start of the experiment.Quantification of the activity at different transit times
After the acquisition, the data were reconstructed itera-
tively with the HiSPECT software (Bioscan Inc.) using
dedicated ordered subsets expectation maximization for
multiplexing multipinhole reconstruction. A region of
interest (ROI) was drawn manually around the transit
portion of the GI tract; the 3D activity distribution
within the ROI was then summed to determine the up-
take on the basis of each frame. Scatter correction was
not performed. All measured activities were corrected
for decay and expressed as percent injected (gavage) ac-
tivity (%IA). The ingested activity was determined by
measuring the syringe in a dose calibrator (Biodex
Atomlab, New York, NY, USA) before and after the oral
gavage of the animal. The difference was defined as the
injected activity. Quantification of the ROI is performed
with the InterView XP software (Mediso Ltd., Budapest,
Hungary).Histological staining
Gastric specimens of normal charcoal gavaged without
radioactive label and charcoal gavaged labeled with 99mTc-
DTPA were fixed in 10% neutral-buffered formalin. The
paraffin-embedded tissues were sectioned and stained with
hematoxylin and eosin for standard histological evaluation.
The stained sections were photographed using a 90I Nikon
microscope with FL/DIC/Phase (Melville, NY, USA).TPA at different time points
I tract
clearly labeled
clearly labeled; leading front is just entering into the cecum
eled; well-defined cecum, transverse colon and large intestinal loops, and
were seen
colon and fecal pellets in the rectum are clearly labeled
stomach (potentially parietal cells accumulating free Tc)
Table 2 Transit measurements in the GI tract using







Transit measurements in the GI tract
1 1 h Stomach and small intestine are very
clearly labeled
2 6 h Stomach and well-defined labeling of
the cecum is seen
3 22 h Transverse colon and cecum are labeled
99mTc-Ch-DTPA 6 hours                       99mTc-Ch-DTPA 6 hours with Loperamide
Figure 4 After 6-h gavaging of 99mTc-Ch-DTPA showing the
movements in the GI tract with and without loperamide.
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The aim of this study was to develop a novel non-
invasive in vivo method for quantifying the gastrointes-
tinal transit in live animals (Figure 1). The conventional
methods of using dye-based transit studies provide only
single time points; thus, longitudinal studies are not pos-
sible. In our study, we used two sets of materials for la-
beling, in order to select the best reagent for these
experiments. Firstly, we labeled the activated charcoal
with 99mTc-DTPA, and in another, unconjugated 99mTc
was mixed with Amberlite resin. The images collected at
3-h time point of both gavaged animals showed signifi-
cant gastrointestinal labeling, but the charcoal gavaged
showed better image than the Amberlite resin (Figure 2).
Although earlier studies, in common brushtail possum
and in dog using gamma scintigraphy, have used 99mTc-
labeled resin for GI motility measurements [11,12], these
proved to be less sensitive than our NanoSPECT99mTc-Ch-DTPA 22 hours 99mTc-Ch-DTPA 22 hours with Loperamide
Figure 5 Movements of 99mTc-Ch-DTPA in the GI tract after 22
h of gavaging with and without loperamide.imaging. Our present study was more sensitive in terms
of binding affinity and measurements with charcoal
compared to 99mTc-labeled resin method.
The images collected at different time points were
processed for extracting different information. It was no-
ticed that 1 h following gavaging, the total charcoal
bolus had entered the stomach and begun entering into
the small intestine. After 3-h transit time, the 99mTc-Ch-
DTPA had labeled almost the entire loop of small intes-
tines and cecum (Figure 3).
After 6 and 8 h, the distinct labeling of 99mTc-Ch-
DTPA was visualized in the cecum, the ascending, trans-
verse, and descending colon, and the rectum (Table 1).
Several pellets were stored in the rectum before
defecation. We conclude that the GI transit time is ap-
proximately 6 h (Figure 4, left). After 22 h following the
gavage, only little radioactivity remained in the stomach
(Figure 5, left) and nothing was seen in the transverse
colon or other location along the GI tract (Table 2). Fur-
thermore, we confirmed the same total transit time by
gavaging trypan blue, a non-radioactive dye, and dissecting
the animals open at different time points to observe the
GI motility. This experiment employing trypan blue also
further confirms that there is no underlying toxicity that
may potentially impair the GI physiology and integrity due
to the use of radioligand in the GI tract. This wasFigure 6 Trypan blue-gavaged animal after 6 h that resembles
a similar total transit time observed with 99mTc-Ch-DTPA.
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time point. Figure 6 shows an animal sacrificed 6 h after
trypan blue gavage. The post-mortem analysis of animals
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Figure 7 Showing 99mTc-Ch-DTPA measurement in different parts of Gdemonstrated that there was no difference in the transit
time between the two methods.
To delineate the pharmacological modification of GI
transit time, we selected the drug, loperamide, administeredement in different parts of GI 
urs 8 hours 22 hours
rement in different parts of GI 
atment
22 hours 22 hours (Lop)
I tract (A and B). Before and after loperamide treatment.
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known to delay the GI transit time in both animals and
humans by activating μ-opioid receptors of the myenteric
plexus. After 6 h of loperamide administration, the animals
showed clear 99mTc-Ch-DTPA labeling in stomach, cecum,
and transverse colon (Figure 4, right). Even imaging 22 h
post-gavage with SPECT showed that both the cecum and
transverse colon retained significant label (Figure 5,
right). To quantify the activity at different time points
post-gavage, charcoal motility was analyzed and calcu-
lated, normalizing all parameters (Figure 7A, B). As
expected, loperamide results in a slower progression of
the radiotracer.
In order to observe any toxicity of the labeled radio-
tracer (99mTc-Ch-DTPA), we fixed the tissues after 5-h
administration of 99mTc-Ch-DTPA at the three regions
of GI tract, namely the stomach, intestine, and colon for
histology. The sections were compared with the normal
tissues at the same locations. The histological sections of
the above tissues showed no significant damage in the
tissue, which suggests that there is no toxicity during the
transit of the 99mTc-Ch-DTPA through the GI tract
(Figure 8).Discussion
The tracing of radiopharmaceuticals in vivo offers immense
potential in order to understand their quantification and
mechanism of action allowing the development and ana-
lysis of new drugs. Non-invasive in vivo imaging, with
quantification methods of radioactive compounds, allows
the determination of the accurate uptake of target mole-
cules. In our study, we used 99mTc-Ch-DTPA which is
unique and efficient for the imaging of the GI tract motil-
ity. In our comparison with the 99mTc-Amberlite resin
and 99mTc-Ch-DTPA for transit motility, the 99mTc-Ch-
DTPA was better retained compared with 99mTc-AmberliteFigure 8 Light microscopy pictures of normal and Tc-Ch-DTPA-
treated sections stained with HE.resin. The same type of scintigraphic measurement has
been reported in humans using activated charcoal [13].
McDowell et al. [14] has reported that the measure-
ments on gastrointestinal tracts of Trichosurus vulpecula
in New Zealand are compared with those of the published
information. Another aspect of the same study is that they
have shown the inter-animal variation in different areas
and the pH of the gastrointestinal tract of individual pos-
sums. So far, one transit time study has been reported with
the fluid and indigestible particles to determine in the
common brushtail possum (T. vulpecula). 99mTc-labeled
resin (anion) particles (sizes ranging from 75 to 125 or
500 to 700 μm diameters) or solution (99mTc-DTPA) was
administered orally. They predetermined the times after
dosing (3, 6, 12, 24, or 32 h), the distribution of radioactiv-
ity measured ex vivo on different time points [12].
In the present study, the GI transit was assessed by
the NanoSPECT using the 99mTc-Ch-DTPA. The spatial
resolution of 0.45 mm allowed the observation of the GI
transit movement with excellent accuracy. We found
that the total GI transit time is around 6 h in mice. Out
of 11 animals scanned, at several time points 0, 1, 3, 6,
8, and 22 h, we found that the entire GI tract was
cleared between 6 and 8 h. Our non-radiolabeled dye
study also supported these findings (data not shown).
The half-life of 99mTc is 6 h; thus, the image obtained
after 22 h in normal mice showed no activity in trans-
verse colon and other location, with only trace amounts
remaining in the stomach, which clearly indicates that
the free 99mTc was accumulated in the labeled parietal
cells present in the stomach.
To validate the toxicity issue of the 99mTc-Ch-DTPA,
the present results, the histology has been obtained at
different regions of the GI tract and there are no signifi-
cant changes in all portions at different times of expos-
ure. This clearly shows that the dose we used on the
basis of animal weight is appropriate for the mice in all
respects. There are reports on the toxicity of the radio-
activity; it is mostly on different organs and not on the
digestive tracts with technetium [15,16].
To test the delay in the transit time, we administered
loperamide. The drug, loperamide, normally slows the
muscular contractions of the intestine and is thus
termed as an antimotility agent. Loperamide acts mainly
on opioid receptors, which are found in the walls lining
the intestines. This reduces the muscular contractions of
the intestine (peristalsis) that move food and fecal mat-
ter through the gut. After 6 h of administration, the GI
tract was labeled only at the stomach, cecum, and trans-
verse colon. This clearly indicates that the drug has tre-
mendous effect of delaying the transit time. Even 22 h
later, the images show the retention of some labeling in
the same structures, further supporting the mechanism
of drug action.
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In summary, we present the first non-invasive radioactive-
based monitoring of gastrointestinal transit time of mouse
in real time, using NanoSPECT, allowing clear depiction
of differences between drug-free and loperamide-treated
animals. Furthermore, it demonstrates the feasibility of
studying the site of release of pharmaceutical compounds
in vivo.
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